Sierra Oncology, Inc.
NNASDAQ:SRRARecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
Company News
GSK Receives Regulatory Nod for Consumer Healthcare Demerger
SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA
SIERRA ONCOLOGY INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Sierra Oncology, Inc - SRRA
Best Biotech Stocks To Buy Now? 5 To Know
SHAREHOLDER ALERT: Weiss Law Investigates Sierra Oncology, Inc.
Late-Stage Biopharmaceutical Sierra Oncology announces acquisition by GSK
Why Is Sierra Oncology (SRRA) Stock Up Today?
Sierra Oncology Stock Is Soaring: Here's Why
Sierra Oncology Stock Soars After Buyout
GSK to buy Sierra Oncology for $1.9 billion
Sierra Oncology Soars After Takeover by Glaxo
Why Sierra Oncology Stock Is Soaring Today
GlaxoSmithKline Scoops Up Rare Cancer-Focused Sierra Oncology In $1.9B Cash Deal
Why GlaxoSmithKline (GSK) Is Buying Sierra Oncology (SRRA) For $1.9 Billion
GlaxoSmithKline to buy Sierra Oncology for $1.9 billion
GSK to buy Sierra Oncology for $1.9 billion
GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bn
Sierra Oncology's Strong Data In Myelofibrosis Challenges MorphoSys And Incyte
Sierra Oncology to Present at B. Riley Securities Oncology Investor Conference
Sierra Oncology: Plenty Of Room To Trade Higher After Latest Myelofibrosis Data